HGF and neoplasm: In contrast, in NSGhHGF H3122 xenografts, capmatinib substantially enhanced the magnitude of tumor regression and delayed the relapse (Fig. 2E, S3F, G), supporting the relevance of the HGF-cMET axis for stroma-mediated resistance in vivo.